Cyclophosphamide (Non-IMP, Lymphodepletion)

OTHER2 trials

Sponsors

AvenCell Europe GmbH, AvenCell Therapeutics, Inc.

Conditions

Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseLeukemia RelapseLeukemia and LymphomaLymphoma Diffuse Large B-cellLymphoma Receiving CAR-T Therapy

Phase 1

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

RecruitingNCT05949125

AvenCell Europe GmbHAcute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Start: 2024-01-03End: 2028-01-31Target: 80Updated: 2025-05-14

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

RecruitingNCT07284433

AvenCell Therapeutics, Inc.Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Diffuse Large B-cell +1

Start: 2026-01-06End: 2029-11-02Target: 178Updated: 2026-08-28

Related Papers

Functional Characterization and Optimization of Switchable Allogeneic Chimeric Antigen Receptor T Cells for Targeting CD19 and CD20 in B Cell Malignancies

Blood2023-11-021 citations